Sentinel lymph node risk prognostication in primary cutaneous melanoma through tissue-based profiling, potentially redefining the need for sentinel lymph node biopsy
Open Access
- 8 March 2024
- journal article
- review article
- Published by Elsevier in European Journal of Cancer
- Vol. 202, 113989
Abstract
No abstract availableKeywords
This publication has 64 references indexed in Scilit:
- Are the MIA and MSKCC nomograms useful in selecting patients with melanoma for sentinel lymph node biopsy?Journal of Surgical Oncology, 2023
- Melanoma classification and management in the era of molecular medicineDermatologic Clinics, 2022
- Identification of stage I/IIA melanoma patients at high risk for disease relapse using a clinicopathologic and gene expression modelEuropean Journal of Cancer, 2020
- The EORTC-DeCOG nomogram adequately predicts outcomes of patients with sentinel node–positive melanoma without the need for completion lymph node dissectionEuropean Journal of Cancer, 2020
- Clinical validation of a prognostic 11-gene expression profiling score in prospectively collected FFPE tissue of patients with AJCC v8 stage II cutaneous melanomaEuropean Journal of Cancer, 2020
- Prospective validation of the prognostic 31‐gene expression profiling test in primary cutaneous melanomaCancer Medicine, 2019
- Performance of a 31‐gene expression profile test in cutaneous melanomas of the head and neckHead & Neck, 2019
- Melanoma subtypes: genomic profiles, prognostic molecular markers and therapeutic possibilitiesThe Journal of Pathology, 2018
- Concordance and Reproducibility of Melanoma Staging According to the 7th vs 8th Edition of the AJCC Cancer Staging ManualJAMA Network Open, 2018
- A nine-gene signature predicting clinical outcome in cutaneous melanomaJournal of Cancer Research and Clinical Oncology, 2012